A case of bronchiolitis obliterans after living-donor renal transplantation.
Acute rejection
Bronchiolitis obliterans
Graft versus host disease
Living-donor renal transplantation
Obstructive lung diseases
Journal
Respiratory investigation
ISSN: 2212-5353
Titre abrégé: Respir Investig
Pays: Netherlands
ID NLM: 101581124
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
08
06
2020
revised:
28
11
2020
accepted:
07
12
2020
pubmed:
2
2
2021
medline:
3
7
2021
entrez:
1
2
2021
Statut:
ppublish
Résumé
We herein report the case of a 20 year-old-man who developed bronchiolitis obliterans after living-donor renal transplantation. The patient presented with dyspnea on exertion and wheezing two years after renal transplantation, and spirometry showed an obstructive pattern. Surgical lung biopsy revealed subepithelial fibrosis that constricted and obstructed the intrabronchiolar space. Based on these findings, the patient was diagnosed with bronchiolitis obliterans. He was prescribed bronchodilators and azithromycin, and he achieved stable respiratory function for two years. The differential diagnosis of respiratory symptoms after renal transplantation includes opportunistic infection and drug-induced lung injury; however, bronchiolitis obliterans should also be considered.
Identifiants
pubmed: 33518470
pii: S2212-5345(20)30188-X
doi: 10.1016/j.resinv.2020.12.003
pii:
doi:
Substances chimiques
Bronchodilator Agents
0
Azithromycin
83905-01-5
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
367-371Informations de copyright
Copyright © 2021 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest M Hayashi, S Hokari, N Aoki, Y Ohshima, T Koya, M Tasaki, and K Saito declare that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article. S Watanabe received a research funding from Boehringer Ingelheim, and T Kikuchi received research funding from Boehringer Ingelheim, Chugai Pharmaceutical, and Eli Lilly.